Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Nov;62(11):5198–5200. doi: 10.1128/iai.62.11.5198-5200.1994

Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.

N Orr 1, R Arnon 1, G Rubin 1, D Cohen 1, H Bercovier 1, G H Lowell 1
PMCID: PMC303249  PMID: 7927807

Abstract

Addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a lipopolysaccharide vaccines improved their immunogenicities. Enhancement of anti-O-Shigella immunoglobulin A levels was most evident in lung lavages following oral immunization and in lung and intestinal fluids when suboptimal doses were used with either immunization route.

Full text

PDF
5198

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham E., Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine. 1991 Oct;9(10):757–764. doi: 10.1016/0264-410x(91)90293-f. [DOI] [PubMed] [Google Scholar]
  2. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  3. Chen K. S., Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. Eur J Immunol. 1990 Feb;20(2):433–436. doi: 10.1002/eji.1830200230. [DOI] [PubMed] [Google Scholar]
  4. Cohen D., Green M. S., Block C., Rouach T., Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988 May;157(5):1068–1071. doi: 10.1093/infdis/157.5.1068. [DOI] [PubMed] [Google Scholar]
  5. Halimi H., Rivaille P. Immune response related to the molecular structure of a peptide from the cholera toxin B subunit. Vaccine. 1993 Sep;11(12):1233–1239. doi: 10.1016/0264-410x(93)90048-3. [DOI] [PubMed] [Google Scholar]
  6. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., Shimada K., Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 1990 Jun;8(3):243–248. doi: 10.1016/0264-410x(90)90053-o. [DOI] [PubMed] [Google Scholar]
  7. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986 Oct;59(2):301–308. [PMC free article] [PubMed] [Google Scholar]
  8. Orr N., Robin G., Cohen D., Arnon R., Lowell G. H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun. 1993 Jun;61(6):2390–2395. doi: 10.1128/iai.61.6.2390-2395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ruedl C., Albini B., Böck G., Wick G., Wolf H., Albin B. Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy. Int Immunol. 1993 Jan;5(1):29–36. doi: 10.1093/intimm/5.1.29. [DOI] [PubMed] [Google Scholar]
  10. Sanchez J. L., Trofa A. F., Taylor D. N., Kuschner R. A., DeFraites R. F., Craig S. C., Rao M. R., Clemens J. D., Svennerholm A. M., Sadoff J. C. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis. 1993 Jun;167(6):1446–1449. doi: 10.1093/infdis/167.6.1446. [DOI] [PubMed] [Google Scholar]
  11. Sugita-Konishi Y., Kumagai S. Biliary immune response to orally presented food antigen, ovomucoid, and its potentiation by cholera toxin B subunit. Scand J Immunol. 1992 May;35(5):597–602. doi: 10.1111/j.1365-3083.1992.tb03259.x. [DOI] [PubMed] [Google Scholar]
  12. Tamura S. I., Samegai Y., Kurata H., Kikuta K., Nagamine T., Aizawa C., Kurata T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989 Jun;7(3):257–262. doi: 10.1016/0264-410x(89)90240-5. [DOI] [PubMed] [Google Scholar]
  13. Vajdy M., Lycke N. Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology. 1992 Mar;75(3):488–492. [PMC free article] [PubMed] [Google Scholar]
  14. Wu H. Y., Russell M. W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun. 1993 Jan;61(1):314–322. doi: 10.1128/iai.61.1.314-322.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES